Investor Presentation

93 Investor presentation First six months of 2022 Novo NordiskⓇ Ziltivekimab aspires to address an unmet need in more than 5 million people Ziltivekimab aspires to reduce MACE in people with ASCVD and CKD Investment Global patients (in millions) 16 12 Approximately 5-8m patients 8 4 0 ASCVD with CKD hsCRP>2 Market building Critical success factors to commercialise ziltivekimab Targeted HCP outreach and relationship building Successful payer engagement • Focus areas • Increase presence with key prescriber base being cardiologists and PCPS Enhance awareness of inflammatory burden in CVD with KOLs and HCP associations Utilise ZEUS read-out to quantify anti- inflammatory clinical benefit in ASCVD patients with CKD vs Standard of Care Integrated evidence generation • Understand hsCRP and inflammation, epidemiology of disease and socio-economic burden of disease ○ Low High 1 Includes US, EU5 (Germany, France, Spain, Italy, United Kingdom) and Japan MACE or major adverse cardiovascular events includes CV death, non-fatal MI or non-fatal stroke; ASCVD: Atherosclerotic cardiovascular disease; CKD: Chronic kidney disease; HCP: Healthcare professional; PCP: Primary care physician KOL: Key opinion leader; hsCRP: High-sensitivity C-reactive protein levels

View entire presentation